Table 4.
Univariate Cox models for OS.
| Variable | Category | HR (95%CI) | p |
|---|---|---|---|
| Treatment | NA-CRT | Reference | |
| Neoadjuvant treatment | NA-CT | 0.49 (0.07,3.54) | 0.476 |
| NA-XRT | 0.59 (0.06,6.36) | 0.667 | |
| Age | One year increased | 0.99 (0.93,1.05) | 0.745 |
| Sex | Female | Reference | |
| Male | 0.12 (0.01,1.03) | 0.054 | |
| Race/Ethnicity | Non-Hispanic White | Reference | |
| Non-Hispanic Black | 1.32 (0.14,12.2) | 0.807 | |
| Hispanic | 0.35 (0.04,3.05) | 0.342 | |
| Asian/Unknown | NE | ||
| Location | Lower extremity | Reference | |
| Upper extremity | 2.34 (0.42,12.9) | 0.330 | |
| Pre-treatment tumor (cm) | <5 | Reference | |
| 5–10 | 0.44 (0.06,3.11) | 0.410 | |
| >10 | 0.35 (0.04,2.92) | 0.331 | |
| Post treatment tumor (cm) | <5 | NE | |
| 5–10 | |||
| >10 | |||
| Unknown | |||
| Histology | Fibrosarcoma/Fibroblastic sarcoma | Reference | |
| Leiomyosarcoma | NE | ||
| Myxoid cell/round cell liposarcoma | NE | ||
| Synovial cell sarcoma | 3.96 (0.65,24.3) | 0.137 | |
| Spindle cell sarcoma | NE | ||
| Grade | 2 | Reference | |
| 3 | 0.56 (0.11,2.79) | 0.476 | |
| Clinical T stage | 1 | Reference | |
| 2 | 0.37 (0.03,4.65) | 0.440 | |
| 3 | 1.04 (0.09,12.7) | 0.977 | |
| 4 | 0.32 (0.02,6.60) | 0.462 | |
| x | 1.91 (0.11,33.0) | 0.656 | |
| Clinical N stage | 0 | Reference | |
| 1 | NE | ||
| x | 3.63 (0.32,41.5) | 0.299 | |
| Clinical M stage | 0 | Reference | |
| 1 | NE | ||
| x | 3.23 (0.30,34.7) | 0.332 | |
| Clinical stage | 2 | Reference | |
| 3 | 0.41 (0.04,4.16) | 0.452 | |
| 4 | 2.81 (0.16,50.3) | 0.483 | |
| x | 1.92 (0.11,33.0) | 0.652 | |
| Pathology complete response | pCR | NE | |
| (pCR) | Non-pCR |
NA-CT: Neoadjuvant chemotherapy; NA-CRT: Neoadjuvant chemoradiation; NA-XRT: Neoadjuvant radiation; NE: Not estimable.